Literature DB >> 17052894

A case of hyperparathyroidism-jaw tumour syndrome found in the treatment of an ossifying fibroma in the maxillary bone.

Y Yamashita1, T Akiyama, N Mizusawa, K Yoshimoto, M Goto.   

Abstract

Hyperparathyroidism-jaw tumour (HPT-JT) syndrome is characterized by parathyroid tumours as well as by ossifying fibromas of the mandible and maxilla, renal cysts, or Wilms' tumours. Recently, the gene responsible for HPT-JT syndrome has been identified as the HRPT2 tumour suppressor gene. In an 18-year-old male, a tumour in the maxilla was first diagnosed as an ossifying fibroma. During biochemical screening before surgery, the patient received a diagnosis of primary hyperparathyroidism. Neck computed tomography scanning showed a parathyroid tumour. Surgical excisions to remove the jaw tumour and parathyroid adenoma were performed. The postoperative course has been uneventful and a follow up at 2 years revealed no evidence of recurrence. The HRPT2 germline mutation of 39delC was detected in the proband, but not in his unaffected parents. These results suggested that the germline mutation occurred de novo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052894     DOI: 10.1016/j.ijom.2006.08.007

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  11 in total

Review 1.  Systematic review of oral manifestations related to hyperparathyroidism.

Authors:  Benjamin Palla; Egon Burian; Riham Fliefel; Sven Otto
Journal:  Clin Oral Investig       Date:  2017-06-14       Impact factor: 3.573

2.  Hyperparathyroidism-jaw tumor syndrome: Results of operative management.

Authors:  Amit Mehta; Dhaval Patel; Avi Rosenberg; Myriem Boufraqech; Ryan J Ellis; Naris Nilubol; Martha M Quezado; Stephen J Marx; William F Simonds; Electron Kebebew
Journal:  Surgery       Date:  2014-10-16       Impact factor: 3.982

3.  Hyperparathyroidism-jaw tumour syndrome detected by aggressive generalized osteitis fibrosa cystica.

Authors:  Alae Guerrouani; Abdelkader Rzin; Karim El Khatib
Journal:  Clin Cases Miner Bone Metab       Date:  2013-01

4.  A Novel Mutation in a Patient with Hyperparathyroidism-Jaw Tumour Syndrome.

Authors:  Virginia Bellido; Ihintza Larrañaga; Maite Guimón; Rafael Martinez-Conde; Asier Eguia; Gustavo Perez de Nanclares; Luis Castaño; Sonia Gaztambide
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

Review 5.  Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Bruno Carnaille; F Fausto Palazzo; Menno Vriens
Journal:  Langenbecks Arch Surg       Date:  2015-10-08       Impact factor: 3.445

Review 6.  Familial Cancers of Head and Neck Region.

Authors:  Reshma Venugopal; Radhika Manoj Bavle; Paremala Konda; Sudhakara Muniswamappa; Soumya Makarla
Journal:  J Clin Diagn Res       Date:  2017-06-01

7.  Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred.

Authors:  Maurizio Iacobone; Giulia Masi; Luisa Barzon; Andrea Porzionato; Veronica Macchi; Francesco Antonio Ciarleglio; Giorgio Palù; Raffaele De Caro; Giovanni Viel; Gennaro Favia
Journal:  Langenbecks Arch Surg       Date:  2009-06-16       Impact factor: 3.445

Review 8.  Two cases of multiple ossifying fibromas in the jaws.

Authors:  Ting-Ting Wang; Ran Zhang; Lin Wang; Yan Chen; Qing Dong; Tie-Jun Li
Journal:  Diagn Pathol       Date:  2014-03-28       Impact factor: 2.644

9.  An adolescent case of familial hyperparathyroidism with a germline frameshift mutation of the CDC73 gene.

Authors:  Takako Takeuchi; Yuko Yoto; Takeshi Tsugawa; Hotaka Kamasaki; Atsushi Kondo; Jiro Ogino; Tadashi Hasegawa; Naoya Yama; Sawa Anan; Shinya Uchino; Aki Ishikawa; Akihiro Sakurai; Hiroyuki Tsutsumi
Journal:  Clin Pediatr Endocrinol       Date:  2015-10-24

Review 10.  Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.

Authors:  Luís Cardoso; Mark Stevenson; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2017-09-25       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.